Effect of Allogeneic Bone-Marrow Derived Mesenchymal Stem Cell Therapy on Quality of Life in Patients with Parkinson’s Disease
Objective: To assess the impact of intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cell (allo-hMSC) infusions on the quality of life (QoL) of patients with…Effects of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy on Motor Complications in Parkinson’s Disease
Objective: To evaluate the impact of intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cell (allo-hMSC) treatment on motor complications in Parkinson’s disease (PD). Background: Motor…Continued Evaluation of Bemdaneprocel Following a Phase 1 Study for Parkinson’s Disease: Outcomes Through 3 Years
Objective: To report the safety and clinical outcomes of bemdaneprocel in participants with Parkinson’s disease (PD) through 3 years post transplantation. Background: Bemdaneprocel is an…Impact of Allogeneic Mesenchymal Stem Cells in Motor and Non-Motor Symptoms of Parkinson’s Disease: A Phase 2 Randomized Trial
Objective: To assess the efficacy of repeated intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cell (allo-hMSC) infusions in reducing motor and non-motor symptoms in people…Cognitive Improvement in Parkinson’s Disease Patients After Intravenous Mesenchymal Stem Cell Infusion: Results from a Phase 2 Randomized Trial
Objective: Assess the impact of treatment with intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cells (allo-hMSCs) on cognition in patients with mild-moderate Parkinson’s Disease (PD).…LRRK2 I1371V Mutation Induces ER Stress, Mitochondrial Dysfunction, and Impaired Mitophagy in Parkinson’s Disease Astrocytes
Objective: This study examines the pathogenic effect of the LRRK2 I1371V mutation on mitochondrial dysfunction, as a result of ER calcium dysregulation, and impaired mitophagy…Evaluation of Perfusion, Iron Deposition, and Neuromelanin MRI Biomarkers Following Mesenchymal Stem Cell Treatment in a Phase 2 Parkinson’s Disease Trial
Objective: Evaluate the effects of allogeneic bone marrow-derived mesenchymal stem cell (allo-hMSC) infusions on neuroimaging biomarkers in patients with Parkinson’s disease (PD) using different MRI…Bayesian Re-Analysis of Phase I and II Subthalamic Nucleus Perfusion Changes Following Mesenchymal Stem Cell Infusion in Parkinson’s Disease
Objective: To compare subthalamic nucleus (STN) perfusion changes following mesenchymal stem cell (MSC) infusion in Parkinson’s disease (PD) using Bayesian methods in both Phase I…The LRRK2 I1371V mutation alters membrane dynamics and inflammatory profile of astrocytes differentiated from LRRK2-I1371V PD Patient iPSCs
Objective: To evaluate the membrane dynamics and inflammatory profile of astrocytes differentiated from LRRK2-I1371V PD iPSCs in the presence and absence of extracellular α-Synuclein. Background:…iPSC-Based Modeling of SCA12 for Targeted Therapeutic Screening
Objective: 1. To identify a cohort of genetically confirmed SCA12 patients of Indian origin, derive iPSCs, progenitor cells and neurons from peripheral blood samples2. To…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 6
- Next Page »